Varlilumab
A monoclonal antibody used in cancer immunotherapy
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Varlilumab (also known as CDX-1127) is a monoclonal antibody that targets the CD27 receptor, a member of the tumor necrosis factor receptor superfamily. It is being investigated for its potential use in cancer immunotherapy.
Mechanism of Action[edit | edit source]
Varlilumab is designed to modulate the immune system by targeting CD27, a co-stimulatory molecule found on T cells. CD27 plays a crucial role in the activation and survival of T cells, which are essential components of the adaptive immune response. By binding to CD27, varlilumab can enhance T cell activation and proliferation, potentially leading to a more robust anti-tumor immune response.
Clinical Development[edit | edit source]
Varlilumab is currently undergoing clinical trials to evaluate its efficacy and safety in treating various types of cancer, including lymphoma, melanoma, and renal cell carcinoma. Early-phase clinical trials have shown promising results, with some patients experiencing tumor shrinkage and prolonged disease stabilization.
Potential Benefits[edit | edit source]
The use of varlilumab in cancer therapy is based on its ability to enhance the body's immune response against tumor cells. By activating T cells, varlilumab may help overcome the immunosuppressive environment often found in tumors, allowing the immune system to effectively target and destroy cancer cells.
Side Effects[edit | edit source]
As with other immunotherapies, varlilumab can cause immune-related adverse effects. These may include cytokine release syndrome, autoimmune reactions, and other inflammatory responses. Close monitoring and management of these side effects are essential during treatment.
Research and Future Directions[edit | edit source]
Ongoing research is focused on optimizing the use of varlilumab in combination with other therapies, such as checkpoint inhibitors and chemotherapy. These combination strategies aim to enhance the overall efficacy of cancer treatment by leveraging multiple mechanisms of action.
Also see[edit | edit source]
 | This immunology article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
